Dihexa

Dihexa (N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, C₂₇H₄₄N₄O₅, molecular weight 504.67 Da) is a small oligopeptide derived from angiotensin IV that binds hepatocyte growth factor (HGF) with high affinity and potentiates its signaling through the c-Met receptor tyrosine kinase. The HGF/c-Met system is a well-characterized pathway in liver regeneration and cancer biology, but its role in the brain — where it regulates synaptic plasticity, dendritic arborization, and neuronal survival — is less widely recognized and represents the therapeutic target for Dihexa.

When Dihexa binds HGF, it enhances HGF's affinity for c-Met, effectively lowering the concentration of endogenous HGF required to activate downstream signaling. The activated c-Met receptor triggers multiple pathways: PI3K/Akt (neuronal survival, anti-apoptotic), MAPK/ERK (synaptic plasticity, spine formation), and STAT3 (transcriptional regulation of neurotrophic genes). In hippocampal neuron cultures, Dihexa treatment produced a robust increase in dendritic spine density and synapse formation — the structural correlates of learning and memory. The original characterization reported Dihexa to be seven orders of magnitude more potent than BDNF in a standard neurotrophic activity assay, though this extraordinary potency claim should be interpreted in the context of the specific in vitro assay used.

Critically, Dihexa is orally bioavailable and blood-brain barrier penetrant — properties achieved through its lipophilic design (the N-terminal hexanoic acid moiety and C-terminal aminohexanoic amide confer significant lipid solubility). This is a major practical advantage over peptide nootropics that require injection or intranasal administration. However, the c-Met receptor is also a recognized oncogene, and the theoretical risk of promoting neoplastic growth through chronic c-Met activation has been a persistent concern — though short-duration animal safety studies have not detected neoplastic induction, and oncogenesis generally requires multiple mutations beyond single-pathway activation.

Dihexa was developed by Joseph Harding and his team at Washington State University in the early 2010s, emerging from a systematic program to develop angiotensin IV analogues that could enhance cognitive function through the HGF/c-Met system. The compound's extraordinary in vitro potency generated significant scientific and media interest, with coverage describing it as a potential breakthrough for Alzheimer's treatment.

M3 Biotechnology (later Athira Pharma) was founded to commercialize the technology and developed fosgonimeton (ATH-1017), a phosphate prodrug of Dihexa with improved pharmaceutical properties. Fosgonimeton advanced to Phase 2/3 clinical trials for Alzheimer's and Parkinson's disease. However, the Phase 2 ACT-AD trial in mild-to-moderate Alzheimer's (2022) did not meet its primary endpoint, though subgroup analyses suggested potential efficacy. As of 2026, the prodrug remains in clinical development, and Dihexa itself is available as a research compound through independent suppliers. The compound occupies an interesting position — one of the few nootropics designed from the ground up using modern medicinal chemistry rather than discovered serendipitously or derived from natural sources.

Store lyophilized Dihexa powder at -20°C in a tightly sealed, desiccated container. The peptide's lipophilic character — conferred by the hexanoic acid and aminohexanoic amide moieties — makes it sensitive to oxidation. Minimize exposure to air and moisture during handling. Stability under optimal conditions is expected to exceed 18 months, though long-term stability data is less extensive than for clinically established peptides.

Dihexa's extremely low water solubility is a key practical consideration. The compound is essentially insoluble in water at neutral pH due to its lipophilic design (which is simultaneously what gives it oral bioavailability and BBB penetration). For injectable research protocols, Dihexa must first be dissolved in a small volume of DMSO (dimethyl sulfoxide), then diluted into sterile saline. The final DMSO concentration should not exceed 5–10% of the total injection volume. Alternatively, oral and sublingual administration protocols bypass the solubility problem entirely and leverage the compound's intrinsic oral bioavailability — a major practical advantage. For sublingual protocols, Dihexa powder can be suspended in a small volume of ethanol or a cyclodextrin-based carrier for transmucosal absorption.